RecruitingPhase 2NCT07252336

A Multicenter Study of CAR-T Cells in Primary Ph+All

A Multicenter Study of CD19 CAR-T Cells in the Treatment of Adult Patients With Primary Ph Chromosome Positive Acute Lymphoblastic Leukemia

Sponsor

Zhejiang University

Enrollment

50 participants

Start Date

Nov 30, 2025

Study Type

INTERVENTIONAL

Conditions

A Multicenter Study of CD19 CAR-T Cells in the Treatment of Adult Patients With Primary Ph Chromosome Positive Acute Lymphoblastic Leukemia

Min Age: 18 Years

Age ≥ 18 years old, gender not restricted;
Subjects diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) in accordance with the 2016 WHO Classification of Acute Leukemias;
Abnormal B cells positive for CD19 and CD22 by immunophenotyping;
Subjects positive for Philadelphia chromosome (Ph chromosome) and BCR/ABL1 fusion gene by chromosomal and corresponding genetic testing;
Newly diagnosed B-ALL patients who have not received treatment with standard chemotherapy regimens;
Serum total bilirubin ≤ 51 μmol/L, serum ALT and AST both ≤ 3 times the upper limit of the normal reference range, and serum creatinine ≤ 176.8 μmol/L;
Left ventricular ejection fraction (LVEF) ≥ 50% as assessed by echocardiography;
Subjects with no active pulmonary infection and oxygen saturation ≥ 92% without oxygen supplementation;
Estimated survival time ≥ 3 months;
ECOG performance status score 0-2;
Females and males of childbearing potential must agree to use appropriate contraceptive measures before enrollment, during study participation, and within 6 months after infusion;
Subjects voluntarily participate in this study and sign the informed consent form.

Subjects with a history of epilepsy or other central nervous system diseases;
Subjects with a prior history of QT interval prolongation or severe cardiac diseases;
Pregnant or lactating women (the safety of this therapy for unborn children is unknown);
Subjects with untreated active infections;
Subjects with serological evidence of chronic hepatitis B virus (HBV) infection who are unable or unwilling to receive standard prophylactic antiviral treatment, or have a detectable HBV viral DNA load; subjects with serological evidence of hepatitis C virus (HCV) infection who have not completed curative treatment or have a detectable HCV viral load;
Human immunodeficiency virus (HIV) antibody positive;
Syphilis antibody positive;
Subjects who have previously received any gene therapy products;
Subjects with other uncontrolled diseases who, in the investigator's judgment, are unsuitable for enrollment;
Any other conditions that, in the investigator's judgment, may increase the risk to the subject or interfere with the study results.